April 02, 2003
SACRAMENTO, Calif., April 2, 2003 – Lipomics Technologies Inc., a privately owned company that specializes in lipid metabolite research and analysis services, today announced that Roger Salquist, the former managing director of Bay City Capital, has joined its board of directors. As the latest addition to the board, Salquist will focus on providing general business guidance and attracting new financing for the company through his wide network of finance and industry contacts.
A founding partner of Bay City Capital, a San Francisco-based merchant bank, Salquist focused on securing first and second round financing and investment for more than 30 life sciences companies.
“We are very pleased to welcome Roger to the board,” said Dr. Charles Soderquist, Lipomics’ chairman. “He brings a wealth of business knowledge and experience to Lipomics that is directly relevant to the company’s business model, along with the critical perspective of a venture capitalist.”
“I am honored to join Lipomics’ board of directors,” said Salquist. “As a member of the board, I look forward to helping identify new business opportunities for the company as well as securing further investment to ensure Lipomics’ continued growth.”
Prior to founding Bay City Capital, Salquist was, for 12 years, the chairman and CEO of Calgene Inc., a Davis, Calif.-based agribusiness biotechnology company, until it was acquired by Monsanto in 1996. He has also served as chairman of the California Industrial Biotechnology Association and was founding chairman of the Biotechnology Industry Association’s Food and Agriculture Division.
In other capacities, he served for six years as a member of the board of trustees of the University of San Francisco and currently serves on the advisory board of the University of Washington Friday Harbor Research Laboratories.
Salquist received his bachelor’s degree from Stanford University in 1963 and a master’s degree in business administration from the Stanford University Graduate School of Business in 1971.